Ad
related to: sanofi-aventis
Search results
Results from the WOW.Com Content Network
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers ...
2004: merger of Aventis with and into Sanofi. The new Sanofi-Aventis Group becomes the world's 3rd largest pharmaceutical company, behind Pfizer and GlaxoSmithKline. Aventis Pasteur, the vaccine division of the Sanofi-Aventis Group, changes its name to Sanofi Pasteur. 2008: Sanofi Pasteur acquires Acambis plc, a biotech company.
Hoechst AG (German pronunciation: [ˈhøːçst]) was a German chemicals, later life sciences, company that became Aventis Deutschland after its merger with France's Rhône-Poulenc S.A. in 1999. With the new company's 2004 merger with Sanofi-Synthélabo, it became a subsidiary of the resulting Sanofi-Aventis pharmaceuticals group.
Sanofi-Aventis explains that this prepares it for a production decline expected after patent expirations of several major drugs derived by synthetic chemistry. The project includes training ...
French pharmaceutical company Sanofi-Aventis (SNY), which has been unsuccessful in its recent courtship of U.S. biotech giant Genzyme (GENZ), announced Thursday it signed a 10-year agreement with ...
Sanofi-Aventis (SNY) reported that its second- quarter profit surged 29.4 percent, helped by favorable exchange rates. Still, even on a constant exchange rate, profit rose 17.2 percent, exceeding ...
Rimonabant is a selective CB 1 receptor blocker and was discovered and developed by Sanofi-Aventis. [6]On 21 June 2006, the European Commission approved the sale of rimonabant in the then-25-member European Union as a prescription drug for use in conjunction with diet and exercise for patients with a body mass index (BMI) greater than 30 kg/m 2, or patients with a BMI greater than 27 kg/m 2 ...
Sanofi plans to advance blood cancer drugs known as anti-CD38, which include Sarclisa, despite GenMab and Johnson & Johnson's strong foothold with Darzalex in the same class.
Ad
related to: sanofi-aventis